[96a5a0]: / output / allTrials / identified / NCT05884801_identified.json

Download this file

330 lines (330 with data), 14.1 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
{
"info": {
"nct_id": "NCT05884801",
"official_title": "A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of QLS1103 in Subjects With Advanced Solid Tumors",
"inclusion_criteria": "* 1. Subjects must voluntarily agree to participate in the trial and sign a written informed consent form;\n* 2. Aged ≥18 years old;\n* 3. Histologically or cytologically confirmed advanced or recurrent or metastatic solid tumor;\n* 4. Failure of adequate standard treatment, or no effective standard treatment;\n* 5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1;\n* 6. Life expectancy ≥12 weeks;\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* 1. Subjects received systemic anticancer therapy within 4 weeks prior to the first dose;\n* 2. Subjects received experimental medication or therapy within 4 weeks prior to the first dose;\n* 3. Subjects received major surgery within 4 weeks prior to the first dose;\n* 4. Persistent toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade >1 severity that is related to prior therapy;\n* 5. Cardiovascular and cerebrovascular diseases with clinical significance;\n* 6. Active gastrointestinal disease or other conditions that significantly interfere with drug absorption.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* 1. Subjects must voluntarily agree to participate in the trial and sign a written informed consent form;",
"criterions": [
{
"exact_snippets": "Subjects must voluntarily agree to participate in the trial",
"criterion": "voluntary agreement to participate",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "sign a written informed consent form",
"criterion": "informed consent form",
"requirements": [
{
"requirement_type": "signed",
"expected_value": true
}
]
}
]
},
{
"line": "* 2. Aged ≥18 years old;",
"criterions": [
{
"exact_snippets": "Aged ≥18 years old",
"criterion": "age",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* 3. Histologically or cytologically confirmed advanced or recurrent or metastatic solid tumor;",
"criterions": [
{
"exact_snippets": "Histologically or cytologically confirmed",
"criterion": "tumor confirmation method",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": [
"histologically",
"cytologically"
]
}
]
},
{
"exact_snippets": "advanced or recurrent or metastatic solid tumor",
"criterion": "tumor stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"advanced",
"recurrent",
"metastatic"
]
}
]
}
]
},
{
"line": "* 4. Failure of adequate standard treatment, or no effective standard treatment;",
"criterions": [
{
"exact_snippets": "Failure of adequate standard treatment",
"criterion": "standard treatment",
"requirements": [
{
"requirement_type": "effectiveness",
"expected_value": false
}
]
},
{
"exact_snippets": "no effective standard treatment",
"criterion": "standard treatment",
"requirements": [
{
"requirement_type": "availability",
"expected_value": false
}
]
}
]
},
{
"line": "* 5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1;",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 1,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "* 6. Life expectancy ≥12 weeks;",
"criterions": [
{
"exact_snippets": "Life expectancy ≥12 weeks;",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* 1. Subjects received systemic anticancer therapy within 4 weeks prior to the first dose;",
"criterions": [
{
"exact_snippets": "Subjects received systemic anticancer therapy within 4 weeks prior to the first dose",
"criterion": "systemic anticancer therapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* 2. Subjects received experimental medication or therapy within 4 weeks prior to the first dose;",
"criterions": [
{
"exact_snippets": "Subjects received experimental medication or therapy within 4 weeks prior to the first dose",
"criterion": "experimental medication or therapy",
"requirements": [
{
"requirement_type": "time since last administration",
"expected_value": {
"operator": "<=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* 3. Subjects received major surgery within 4 weeks prior to the first dose;",
"criterions": [
{
"exact_snippets": "Subjects received major surgery within 4 weeks prior to the first dose",
"criterion": "major surgery",
"requirements": [
{
"requirement_type": "time since surgery",
"expected_value": {
"operator": "<=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* 5. Cardiovascular and cerebrovascular diseases with clinical significance;",
"criterions": [
{
"exact_snippets": "Cardiovascular and cerebrovascular diseases with clinical significance",
"criterion": "cardiovascular diseases",
"requirements": [
{
"requirement_type": "clinical significance",
"expected_value": true
}
]
},
{
"exact_snippets": "Cardiovascular and cerebrovascular diseases with clinical significance",
"criterion": "cerebrovascular diseases",
"requirements": [
{
"requirement_type": "clinical significance",
"expected_value": true
}
]
}
]
},
{
"line": "* 6. Active gastrointestinal disease or other conditions that significantly interfere with drug absorption.",
"criterions": [
{
"exact_snippets": "Active gastrointestinal disease",
"criterion": "gastrointestinal disease",
"requirements": [
{
"requirement_type": "activity",
"expected_value": true
}
]
},
{
"exact_snippets": "other conditions that significantly interfere with drug absorption",
"criterion": "conditions interfering with drug absorption",
"requirements": [
{
"requirement_type": "interference",
"expected_value": "significant"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [
{
"line": "* 4. Persistent toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade >1 severity that is related to prior therapy;",
"criterions": [
{
"exact_snippets": "Persistent toxicity ... NCI CTCAE Grade >1 severity ... related to prior therapy",
"criterion": "persistent toxicity",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": ">",
"value": 1,
"unit": "NCI CTCAE Grade"
}
},
{
"requirement_type": "relation to prior therapy",
"expected_value": true
}
]
}
]
}
],
"failed_miscellaneous": []
}